20172019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2019

Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T. C., Tiong, I. S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., Colland, F. & 7 others, Segal, D., Huang, D., Roberts, A. W., Maragno, A. L., Lessene, G., Geneste, O. & Wei, A. H., 1 Apr 2019, In : Leukemia. 33, a, p. 905-917 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
33 Citations (Scopus)

Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study

Wei, A. H., Strickland, S. A., Hou, J. Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., Chyla, B., Popovic, R., Salem, A. H., Agarwal, S., Xu, T., Fakouhi, K. M., Humerickhouse, R., Hong, W. J., Hayslip, J. & Roboz, G. J., 20 May 2019, In : Journal of Clinical Oncology. 37, 15, p. 1277-1284 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
112 Citations (Scopus)
2017

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

Tan, P., Tiong, I. S., Fleming, S., Pomilio, G., Cummings, N., Droogleever, M., McManus, J., Schwarer, A., Catalano, J., Patil, S., Avery, S., Spencer, A. & Wei, A., 2017, In : Oncotarget. 8, 32, p. 52269-52280 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access